Reuters Events' Cell & Gene Therapy USA

Reuters Events 2 November 2020, Virtual Event, USA.
Join 2500+ gene and cell therapy leaders for this (free to attend) conference brough to you by Reuters Events.

The race to commercialize cell & gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market.

With so few treatments on the market to benchmark against, and a relatively unknown understanding of the long-term patient journey, the industry knows it has huge challenges to overcome.

It's not good enough to sell patients and physicians on the dream. We must forge the way alongside government and payers to build new reimbursement models, and scale manufacturing with the optimal patient journey at the centre. All of this while continuing to identify new patient populations to ensure long-term commercial success.

Reuters Events' Cell & Gene Therapy Conference will bring together every key stakeholder to define commercialization approaches and get your solution to patients faster.

Exceptional online networking opportunities

You won't find an online cell and gene commercialization networking experience elsewhere. Reuters Events Pharma Cell & Gene Therapy USA 2020 is the only place to connect with commercialization leaders, patient experience experts, pricing and policy advisors, engagement and education front-runners.

Here's how:

  • Connect 1-on-1 with fellow attendees: Over several weeks, you'll have access to our online messaging platform, allowing you to connect with like-minded pharma leaders and set up a virtual coffee or formal meeting in your own time.
  • Interactivity: With 15+ interactive sessions including virtual workshops, live Q&As and panels, make your voice heard as a thought leader via the speaker question and messaging functions.

For further information and to register, please visit:
https://www.reutersevents.com/events/cellandgene

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Positive new data for Johnson & Johnson single…

Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly sp...

GSK and Alector announce global collaboration in i…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical...

Tezepelumab granted Priority Review by U.S. FDA

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelu...

One shot of the Sputnik V vaccine triggers strong …

A single dose of the Sputnik V vaccine may elicit significant antibody responses against SARS-CoV-2, finds a study published July 13 in the journal Cell Reports Medicine...

Are silver nanoparticles a silver bullet against m…

Antimicrobials are used to kill or slow the growth of bacteria, viruses and other microorganisms. They can be in the form of antibiotics, used to treat bodily infections...

"Long COVID": More than a quarter of COV…

In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight mon...

mRNA vaccines slash risk of COVID-19 infection by …

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of ...

Cancer cells eat themselves to survive

It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwis...

U.S. FDA grants Priority Review for the Biologics …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation for the Biologics Li...

Collaboration between AbbVie, Biogen and Pfizer cr…

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequenc...

Artificial intelligence could be new blueprint for…

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses...

Anti-tumor agent from the intestine

It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseas...